Feature|Articles|September 1, 2026

Exploring the Real Reasons Why RBQM Implementation Fails

RBQM implementations fail not because the software is wrong — but because the human environment surrounding it was never engineered.

There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be technical. It was the wrong platform. The dashboards lack clarity. The vendor overpromised and under-delivered. This myth suggests that if a new system is chosen, the failure will be resolved.

Related to this article

October 16th, 2026

EMA Steps Up Push for Greater Clinical Trial Transparency

European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.

October 14th, 2026

FDA Launches Rare Disease Framework Initiative

FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.

October 22nd, 2026

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

October 22nd, 2026

Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma

Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.

October 22nd, 2026

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

FDA has granted accelerated approval to Ultomiris based on Phase III data showing a 43.4% placebo-adjusted reduction at 34 weeks.

The FDA cleared GSK’s bepirovirsen as add-on therapy for chronic hepatitis B, based on phase 3 trials in which 19% of patients reached functional cure. Credit: Stock.Adobe.com/Destina

October 21st, 2026

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.

October 21st, 2026

The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals

Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.

October 20th, 2026

METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies

METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.